Allergan, Inc.

Jane-Guo Shiah

Thierry Nivaggioli

Wendy M Blanda

David A Weber

Lin Peng

Rahul Bhagat

David Chou

Patrick Michael Hughes

Thomas C Malone

Joan-En Chang-Lin

Jeffrey L Edelman

Gerald Woodrow DeVries

Lon T Spada

Chetan Pujara

Gerald W De Vries

Jeffery L Edelman

Qing Lin

Joan-En Lin

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

Biodegradable intravitreal tyrosine kinase implants

The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.

Ocular implant made by a double extrusion process

Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.

Sustained drug delivery implant

Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.

Extended release biodegradable ocular implants

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods

Growing community of inventors

Irvine, CA, United States of America

Jane-Guo Shiah